**Summary of Surgical Innovations Group PLC Half-Year Report (H1 2025)**
**Financial Highlights**
**Revenues** £6.15 million, stable compared to H1 2024 (£6.18 million).
**Gross Profit Margin** 31.3%, up from 28.8% in FY 2024 but down from 32.9% in H1 2024.
**Adjusted EBITDA** £0.37 million (H1 2024: £0.0 million).
**Adjusted Operating Profit** £0.06 million (H1 2024: £0.43 million loss).
**Adjusted EPS** 0.002p profit per share (H1 2024: 0.040p loss).
**Net Debt** £0.8 million (31 Dec 2024: £0.3 million).
**Gross Cash Headroom** £0.5 million (31 Dec 2024: £0.9 million), increased to £0.8 million by 31 August 2025.
**Commercial and Operational Highlights**
**SI-Branded Products** 37% growth in key European markets, driven by sustainability initiatives.
**Geographic Performance** European growth offset flat UK sales and headwinds in the USA, APAC, and ROW.
**New Product Success** Strong UK sales of the newly introduced Aspen portfolio.
**Regulatory Compliance** Achieved full MDR compliance, with the Logi range recommended for certification.
**Sustainability Impact** Enhanced sustainability training and marketing positively influenced key markets, particularly in Europe.
**Current Trading & Outlook**
**International Momentum** Sustained growth in Europe and strong performance expected in Japan.
**UK Recovery** Recent sales team investment and new product introductions are driving growth.
**US Challenges** Tariffs and market access issues persist, but sustainability initiatives and SI-branded products maintain robust sales.
**Product Innovation** Upcoming launch of LogiTube Lux and expansion of the YelloPort Elite range.
**Cost Reduction** Initiatives underway, with meaningful margin benefits expected from early 2026.
**Long-Term Positioning** Well-positioned for sustained growth and margin expansion.
**Chairman’s Statement**
**Cost Efficiencies** Benefits from the 2024 improvement and cost reduction program are materializing, with further efficiencies expected in H2 2025.
**Market Challenges** Persistent challenges in the UK and USA, but actions taken (e.g., new product ranges, strengthened sales teams) are expected to support recovery.
**OEM Sales** Below prior year due to normalized demand but expected to improve modestly in H2 2025 and H1 2026.
**Strategic Confidence** The Board remains confident in navigating near-term headwinds and delivering sustainable growth and enhanced returns over the medium to long term.
**Operational and Regulatory Activities**
**MDR Compliance** Full compliance achieved, with the Logi range certification representing a major milestone.
**Operational Improvements** Manufacturing efficiency enhancements and cost reductions are delivering benefits.
**Leadership** New Production Director appointed to drive greater operational efficiency.
**Financial Position and Cash Flow**
**Cash Used in Operations** £0.20 million in H1 2025.
**Investments** Continued R&D and capital expenditure to support innovation and growth.
**Going Concern** Directors have a reasonable expectation of adequate resources for the foreseeable future.
**Conclusion**
Surgical Innovations Group PLC demonstrated resilience in H1 2025, with stable revenues and improved profitability driven by cost efficiencies and strong performance in key markets. Despite challenges in the UK and USA, strategic initiatives, product innovation, and sustainability focus position the Group for sustained growth and margin expansion in the medium to long term.